The data shown below were collected from the profiles of 20 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Evaluation of Metformin on Cognitive Improvement in Patients With Non-dementia Vascular Cognitive Impairment and Abnormal Glucose Metabolism
|
|---|---|
| Published in |
Frontiers in Aging Neuroscience, July 2018
|
| DOI | 10.3389/fnagi.2018.00227 |
| Pubmed ID | |
| Authors |
Yufeng Lin, Kaiyuan Wang, Chunchao Ma, Xuesong Wang, Zhongying Gong, Rui Zhang, Dawei Zang, Yan Cheng |
| Abstract |
Objective: Recent studies have suggested that metformin can penetrate the blood-brain barrier, protecting neurons via anti-inflammatory action and improvement of brain energy metabolism. In this study, we aim to investigate the effect of metformin on cognitive function in patients with abnormal glucose metabolism and non-dementia vascular cognitive impairment (NDVCI). Methods: One hundred patients with NDVCI and abnormal glucose metabolism were randomly allocated into two groups: metformin and donepezil (n = 50) or acarbose and donepezil (n = 50). The neuropsychological status, glucose metabolism, and common carotid arteries intima-media thickness (CCA-IMT) before and after a year of treatment, were measured and compared between the groups. Results: Ninety four patients completed all the assessment and follow-up. After a year of treatment, there was a decrease in Alzheimer's disease Assessment Scale-Cognitive Subscale scores and the duration of the Trail Making Test in the metformin-donepezil group. Furthermore, these patients showed a significant increase in World Health Organization-University of California-Los Angeles Auditory Verbal Learning Test scores after treatment (all P < 0.05). However, there was no obvious improvement in cognitive function in the acarbose-donepezil group. We also observed a significant decrease in the level of fasting insulin and insulin resistance (IR) index in the metformin-donepezil group, with a lower CCA-IMT value than that in the acarbose-donepezil group after a year of treatment (P < 0.05). Conclusion: We conclude that metformin can improve cognitive function in patients with NDVCI and abnormal glucose metabolism, especially in terms of performance function. Improved cognitive function may be related to improvement of IR and the attenuated progression of IMT. Trial Registration: ChiCTR-IPR-17011855. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 15% |
| Unknown | 17 | 85% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 17 | 85% |
| Practitioners (doctors, other healthcare professionals) | 2 | 10% |
| Scientists | 1 | 5% |
Mendeley readers
The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 93 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 11% |
| Student > Ph. D. Student | 9 | 10% |
| Student > Master | 8 | 9% |
| Student > Bachelor | 7 | 8% |
| Other | 6 | 6% |
| Other | 13 | 14% |
| Unknown | 40 | 43% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 12% |
| Biochemistry, Genetics and Molecular Biology | 9 | 10% |
| Nursing and Health Professions | 3 | 3% |
| Neuroscience | 3 | 3% |
| Other | 8 | 9% |
| Unknown | 46 | 49% |
Attention Score in Context
This research output has an Altmetric Attention Score of 62. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#732,979
of 26,503,921 outputs
Outputs from Frontiers in Aging Neuroscience
#165
of 5,721 outputs
Outputs of similar age
#14,885
of 345,569 outputs
Outputs of similar age from Frontiers in Aging Neuroscience
#3
of 88 outputs
Altmetric has tracked 26,503,921 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,721 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,569 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.